Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer|
|Citation:||The Journal of Urology, 2015; 194(2):343-349|
|Kathryn T. Dinh, Brandon A. Mahal, David R. Ziehr, Vinayak Muralidhar, Yu-Wei Chen, Vidya B. Viswanathan, Michelle D. Nezolosky, Clair J. Beard, Toni K. Choueiri, Neil E. Martin, Peter F. Orio, Christopher J. Sweeney, Quoc D. Trinh and Paul L. Nguyen|
|Abstract:||Purpose: We determined the incidence of pathological upgrading and up staging for contemporary, clinically low risk patients, and identified predictors of having occult, advanced disease to inform the selection of patients for active surveillance. Materials and Methods: We studied 10,273 patients in the SEER database diagnosed with clinically low risk disease (cT1c/T2a, prostate specific antigen less than 10 ng/ml, Gleason 3þ3¼6) in 2010 to 2011 and treated with prostatectomy. The primary outcome was the incidence of upgrading to pathological Gleason score 7-10 or up staging to pathological T3-T4/N1 disease. Multivariable logistic regression of cases with complete biopsy data (5,581) identified significant predictors of upgrading or up staging, which were then used to create a risk stratification table. Results: At prostatectomy 44% of cases were upgraded and 9.7% were up staged. Multivariable analysis of 5,581 patients showed age, prostate specific antigen and percent positive cores (all p <0.001) but not race were associated with occult, advanced disease. With these variables dichotomized at the median, age older than 60 years (AOR 1.39), prostate specific antigen greater than 5.0 ng/ml (AOR 1.28) and more than 25% positive cores (AOR 1.76) were significantly associated with upgrading (all p <0.001). Similarly, age older than 60 years (AOR 1.42), prostate specific antigen greater than 5.0 ng/ml (AOR 1.44) and more than 25% positive cores (AOR 2.26) were associated with up staging (all p <0.001). Overall 60% of 5,581 low risk cases with prostate specific antigen 7.5 to 9.9 ng/ml and more than 25% positive cores were upgraded. This study is limited by possible bias introduced by only using patients selected for prostatectomy. Conclusions: Nearly half of clinically low risk patients harbor Gleason 7 or greater, or pT3 or greater disease, and should be risk stratified by prostate specific antigen and percent positive cores for consideration of further testing before deciding on active surveillance.|
|Keywords:||neoplasm grading; neoplasm staging; prostatic neoplasms; SEER program; watchful waiting|
|Rights:||© 2015 by American Urological Association Education and Research, Inc.|
|Appears in Collections:||Aurora harvest 7|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.